To observe the clinical efficacy and prognosis of nimotuzumab combined with intensity modulated radiotherapy(IMRT) in the treatment of advanced local nasopharyngeal carcinoma.

82 patients with advanced nasopharyngeal carcinoma were selected, and they were randomly divided into observation group(40 cases) and control group(42 cases) according to the digital table. The observation group was treated with nimotuzumab plus IMRT plus cisplatin, and the control group was treated with IMRT plus cisplatin. After 7 weeks of treatment, the clinical efficacy, adverse reactions and T cell subsets were observed. And the patients were followed up for 1 year, 2 years and 3 years to evaluate the survival rate.

In the observation group, the total remission rate was 75.00%, which was higher than that in the control group(59.09%), the difference was statistically significant(χ²=35.81, P<0.05). The CD₄⁺, CD₈⁺ and CD₄⁺/CD₈⁺ levels in the observation group were similar to those in the control group(tCD₄⁺=0.59, P=0.56; tCD₈⁺=1.70, P=0.01; tCD₄⁺/CD₈⁺=0.13, P=0.89). The incidence rates of Ⅰ degree and Ⅱ degree mucosal reaction and dermatitis in the observation group were 35.00%, 40.00%, 40.00%, 35.00%, respectively, which were higher than 9.09%, 9.09%, 9.09%, 9.09% of the control group, the differences were statistically significant(χ_{Ⅰmucous membrane}²=4.18, P=0.04; χ_{Ⅱmucous membrane}²=5.52, P=0.02; χ_{Ⅰdermatitis}²=5.52, P=0.02; χ_{Ⅱdermatitis}²=4.18, P=0.04). The 2-year and 3-year survival rates in the observation group were 65.50%, 60.00%, respectively, which were significantly higher than 31.82%, 27.27% in the control group, the differences were statistically significant(χ²=4.11, P=0.04; χ²=4.58, P=0.03).

Nimotuzumab combined with IMRT in the treatment of advanced nasopharyngeal carcinoma has good short-term clinical efficacy, good long-term efficacy and controllable adverse reactions. It is worthy of clinical application.

Nasopharyngeal neoplasms; Radiotherapy, intensity-modulated; Nimotuzumab